secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orthofix Medical Inc. (OFIX)
CIK:        0000884624
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000950170-23-061122
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orthofix Q3 net sales $184M (+61% reported, +8% pro forma); GAAP EPS -$0.77, adj. $0.07
--------------------------------------------------------------------------------

- Net sales $184M, +61% reported, +8% pro forma (excl. one-time stocking order); Bone Growth Therapies +15%.
- GAAP net loss $28.9M ($0.77/share); adjusted net income $2.7M ($0.07/share); adjusted EBITDA $13.5M (7.3% of sales).
- Entered new $150M financing agreement (Nov 6, 2023), replaced prior $175M revolver; cash $33.7M at Sep 30.
- Updated 2023 net sales guidance lowered to $739M-$744M (prev $752M-$758M); adjusted EBITDA guidance unchanged $42M-$46M.
- Management transition: Catherine Burzik (Chair) as Interim CEO after board investigation led to departure of three former executives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/884624/000095017023061122/0000950170-23-061122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/884624/000095017023061122/ofix-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer